Table 2

Breakdown of antipsychotic prescribing patterns

TotalCohort C
PrescribingBaseline (1 January 2009)Month 48 (31 December 2012)Baseline (1 January 2009)Month 48 (31 December 2012)
PP, %
All antipsychotics
 Mean (SD)18.0 (±12.0)19.0 (±15.2)18.3 (±11.9)18.0 (±12.3)
 Median (IQR)15.2 (11.8)15.4 (14.0)15.3 (11.4)15.1 (12.7)
SGAs
 All SGAs12.514.612.813.9
  Quetiapine5.14.74.93.9
  Risperidone4.05.34.26.4
  Olanzapine2.13.02.32.9
FGAs
 All FGAs5.95.45.85.2
  Haloperidol2.53.02.32.4
Daily dosage, %*
Recommended98.7NA98.6NA
High0.3NA0.3NA
Excessive1.0NA1.1NA
Length of exposure, %
Recommended18.012.818.210.2
Acceptable12.39.712.26.4
Excessive69.777.669.783.5
  • *Percentage of total prescriptions with following daily dosage: ‘recommended’ ≤ maximum IDD; ‘high’ >100–200% IDD; ‘excessive’ >200% IDD.

  • †Percentage of risperidone prescriptions with following LOE: ‘recommended’ ≤6 weeks; ‘acceptable’ >6 to <12 weeks; ‘excessive’ ≥12 weeks.

  • FGAs, first-generation antipsychotics; IDD, indicative maximum daily dosage; LOE, length of exposure; NA, not applicable; PP, point prevalence; SGAs, second-generation antipsychotics.